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Summary 
Monocyte chemoattractant protein (MCP)-I analogues were designed to determine the role of 
the NH2-terminal region in structure and function. The NH2-terminal residue was important 
for function and receptor binding, as it could not be deleted or extended. However the NHz- 
terminal pyroglutamate residue of the wild type was not essential as it could be replaced by 
several other noncyclic amino acids without loss of activity. Residues 7-10 were essential for 
receptor desensitization, but were not sufficient for function, and the integrity of residues 1-6 
were required for functional activity. A peptide corresponding to MCP-1, 1-10 lacked detectable 
receptor-binding activities, indicating that residues 1-10 are essential  for MCP-1 function, but 
that other residues are also involved. Several truncated analogues, including 8-76, 9-76, and 10-76, 
desensitized MCP-l-induced Ca  2+ induction, but were not significantly active. These analogues 
were antagonists of MCP-1  activity with the most potent being the 9-76  analogue (ICs0 = 
20 nM). The 9-76 specifically bound to MCP-1 receptors with a Ka of 8.3 riM, which was three- 
fold higher than MCP-1  (Kd 2.8  nM).  The 9-76  analogue desensitized the Ca  2+  response to 
MCP-1 and MCP-3, but not to other CC chemokines, suggesting that it is MCP receptor specific. 
The availability  of these compounds will be helpful in evaluating MCP receptor antagonists as 
anti-inflammatory therapeutics. 
M  onocyte chemoattractant protein (MCP)I-1 is a mem- 
￿9  ber of the chemotactic cytokine (chemokine) superfa- 
mily of inflammatory mediators (1, 2). The human chemokines 
can be divided into two families based on sequence similarity: 
the CC family, which includes MCP-1, for which the first 
two cysteines are adjacent; and the CXC family, e.g., IL-8, 
for which the first two cysteines are separated by one residue 
(1, 2).  Besides  MCP-1  (3), the human CC family also in- 
cludes: MCP-2  (4) (also  termed HC14)  (5);  MCP-3 (6);  a 
protein that is regulated on activation, and normal T cell ex- 
pressed and secreted (RANTES) (7); macrophage inhibitory 
protein (MIP)-lol (8)  (first  identified in humans as LD78) 
(9); MIP-1B (8) (human ACT-2) (10); and 1-309 (11). Whereas 
all these CC chemokines have been described as monocyte 
chemoattractants with varying potencies (4, 12, 13, 14), they 
diverge in their functional activities on other cell types, such 
as basophils (15), eosinophils (15,  16), T lymphocytes (17), 
and hemopoietic cells (18). The receptor interactions of the 
1Abbreviations used in this~per: Aba, ot aminobutyric  acid; Ac, acetyl;  nVal, 
norvaline; MCP, monocyte  chemoattractant  protein; MIP, macrophage 
inflammatory  protein; RANTES, regulated  on activation, normal  T cell 
expressed and secreted￿9 
CC chemokines are also complex. Two receptors have been 
sequenced:  one for MIP-lc~, which also  cross-reacts with 
RANTES (19-21),  and recently a receptor for MCP-1 (22). 
However, binding and cross-desensitization studies suggest 
that additional receptors also exist for RANTES (23) (which 
may cross-react with MCP-3) (15), and a promiscuous receptor 
that binds MCP-1, MIP-lc~, and RANTES (23). Cellular ex- 
pression and functional activities that are mediated by the 
various receptors are still  unclear￿9 
MCP-1 has been implicated in a number of allergic and 
chronic inflammatory diseases (24), such as arthritis (25, 26), 
arteriosclerosis (27,  28), and various lung diseases (24,  29). 
In these conditions, monocyte infiltration may be a key early 
event in disease progression. Experimentally, MCP-l-neu- 
tralizing antibodies inhibited immune complex alveoIitis in 
the rat  (29).  Receptor  antagonists  for MCP-1  and  other 
chemokine receptors are an alternative approach to blocking 
MCP-1 actions and could potentially provide novel anti-inflam- 
matory therapeutics. Development of such molecules requires 
knowledge of the residues that are involved in binding as well 
as those required for receptor functions. However, as yet there 
is little information regarding the structural requirements for 
function of MCP-1 or other CC chemokines. In this study 
we examine structure-activity relationships of MCP-1 focusing 
particularly on the NH2-terminal region which, by analogy 
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The results demonstrate the importance of the integrity of 
residues 1-10, for MCP-1 receptor binding and activity. Fur- 
thermore, function and receptor binding is dissociated in several 
truncated  analogues  (8-76,  9-76,  10-76,  and  11-76),  which 
are receptor  antagonists. 
Materials  and  Methods 
Synthetic Proteins.  The human chemokines and their analogues 
were synthesized using tertiary N~-butyloxycarbonyl amino acid 
chemistry on an automated peptide synthesizer (model 430A; Ap- 
plied Biosystems, Foster City, CA) using methods described in de- 
tail elsewhere (33). After hydrogen fluoride deprotection, the poly- 
peptides were folded using air oxidation and purified by reverse 
phase HPLC as described (33). The molecular weights of the syn- 
thetic proteins were determined by electrospray mass spectrometry 
(AP-III, PE-SCIEX; Thomhill, ON) (33). Acetylation of the NH2 
terminus was carried out immediately before hydrogen fluoride 
deprotection using acetic anhydride (10%) in dimethylformamide. 
Chemokines  and  peptides  with  NH2-terminal  glutamine  were 
converted to pyroglutamate by treatment for three days with 1% 
acetic acid in H20. Conversion was readily monitored because of 
the longer HPLC retention time of the pyroglutamate form and 
confirmed by the  17-Da difference  in molecular mass. 
Cell Preparations.  Human monocytes were isolated from burly 
coats of normal donor blood. The cell suspension was loaded on 
Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) and centrifuged at 
400 g for 25 min, followed by density centrifugation on a discon- 
tinuous  Percoll (Pharmacia) gradient at 500 g  for 30 min.  Cells 
with a density of 1.051-1.053  (g/ml) were >70%  monocytes by 
morphology and were used for the chemotaxis assay. The mono- 
cytic cell line THP-1 was obtained from the American Type Cul- 
ture Collection (Rockville, MD) and maintained in R.PMI 1640 
medium supplemented with  10%  FCS. 
Chemotaxis.  Cell migration was assayed using 48-well micro- 
chemotaxis chambers (Neuroprobe,  Cabin John,  MD).  Peptides 
were dissolved in RPMI containing 0.5  mg/ml BSA,  diluted in 
the  same medium  and  26-gl aliquots  were added  to  the  lower 
chamber. A 5-tim pore size polycarbonate filter membrane (Nucleo- 
pore, Pleasanton,  CA) was sandwiched between the lower and upper 
chamber.  Cells,  50/zl of 107/ml  suspension,  were added  to the 
upper chamber. After incubation for 2 h at 37~  in 5% CO2 in 
air, the filter was removed, fixed,  and stained with Canco Quik 
Stain II (Baxter, McGaw Park, IL). The migrated cells were counted 
and the chemotactic index determined as the ratio of the migrated 
cells in the presence of sample, to the control migration in the ab- 
sence  of sample. 
Analysis of Cytosolic-free Calcium.  THP-1 cells (4  x  10  s) were 
loaded with 12.5 gg/ml Fluo-3AM in PBS saline with 0.38 mg/ml 
Pluronic F127  (Molecular Probes, Eugene,  OR.) at 37~  for 30 
min. After washing with PBS, the cells were resuspended in 25 
mM Hepes, 140 mM NaC1,  10 mM glucose,  1.8 mM CaC12, 1 
mM MgC12, and 3 mM KC1, pH 7.3. The fluorescence was moni- 
tored at 7-s intervals over 150 s, after addition of test sample. Max- 
imum Ca  2§  levels were established using Fluo-3AM (designated 
100%  saturation) for each set of measurements by addition of 5 
/xM  Ionomycin  (Sigma  Chemical  Co.,  St.  Louis,  MO).  Ca  2+ 
desensitization was performed by addition of one ligand, and then 
after 150 s the cells were treated again with either the same or 
a different ligand. 
Receptor Binding.  MCP-1 (10 ug) was labeled with monoiodi- 
nated  Bolton-Hunter reagent  (spedfic activity 2,200  Ci/mmol; 
DuPont,  Wilmington,  DE) at 4~  for 30 min. The specific ac- 
tivity of l~5I-labeled MCP-1 was 130 Ci/mmol. To determine the 
binding kinetics,  THP-1 cells (5  x  106) in 200 ul of binding buffer 
(RPMI 1640,  0.5  mg/ml BSA,  50 mM Hepes, and 0.1% NAN3) 
were incubated with varying concentrations of ~I-MCP-1 at 4~ 
for 30 min. The cells were pelleted through a mixture of diacetyl- 
phthalate and dibutylphthalate and radioactivity that was cell as- 
sociated was counted (total binding). Nonspecific binding was de- 
termined in the presence of a 100-fold concentration of unlabeled 
ligand and was subtracted from the total binding.  Kinetic parameters 
(Kd and receptor number) were determined by Scatchard analysis. 
The competition assay was performed with 4 nM of t2SI-MCP-1 
in the presence or absence of varying concentrations of unlabeled 
ligand as described above. 
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Figure  1.  Chemotactic activity of CC chemokines. Migration of mono. 
cytes (A) and THP-1 cells (B) at the indicated chemokine concentrations 
are  shown  as  the  mean  _+  SD  of triplicate determinations.  All  the 
chemokines had significant activity and MCP-1 was significantly  different 
from the others (p <0.05).  Results presented are representative of three 
experiments. 
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Synthesis and Characterization of Analogues.  CC chemo- 
kines were synthesized according to the primary structures 
of the secreted forms. These were MCP-1 (34),  MCP-3 (4), 
MIP-lc~ (35),  MIP-1B (10), and RANTES (7).  The average 
measured synthetic yields were 99.3% per residue. Overall 
yields of pure folded protein were 20-50 rag. The synthetic 
products, including all of the MCP-1 analogues, were found 
to fold spontaneously as indicated by the absence of free thiols 
and the characteristic shift in HPLC retention time that is 
observed on folding of chemokines (33, 36). The 11-76 ana- 
logue was acetylated as other studies had indicated that this 
was required for folding of analogues with NH2-terminal 
cysteine (30). For MCP-1, it was found that this was not re- 
quired, and 11-76 and Ac 11-76 were equivalent. The full- 
length MCP-1 and MCpo3 proteins were converted to the 
NH2-terminal pyroglutamate form before folding and this 
form was then isolated as a homogenous product. The prod- 
ucts eluted as a single peak on reverse phase HPLC and gave 
a single band on analytical isoelectric focusing (30, 33, data 
not shown). The measured average molecular masses of the 
proteins were within experimental error (0.9 amu average) 
of the mass calculated from their target folded covalent struc- 
tures (not shown). 
Comparison of CC Chemokine  Activities.  The chemotactic 
activities of the synthetic CC chemokines were compared 
using peripheral blood monocytes and THP-1 cells as targets 
(Fig. 1). MCP-1 consistently gave the highest level of migra- 
tion and was the most potent inducer with both cell sources. 
The related chemokine MCP-3 (71% identity to MCP-1) also 
gave  significant chemotaxis, but  was  less potent.  MCP-3 
was around 10-fold less potent than MCP-1, but was active 
over the same concentration range. RANTES, MIP-lol, and 
MIP-13 had detectable but lower activity than MCP-1  or 
MCP-3. In general, results with THP-1 cells were found to 
parallel findings with monocytes and thus THP-1 cells were 
used in subsequent assays. 
Role of the NH2-terminal Residue.  The natural forms of 
MCP-1 and MCP-3 are blocked at the NH2 terminus (4, 34). 
This  is  because  after removal  of the  signal  peptide,  the 
NH2-terminal glutamine spontaneously converts to pyroglu- 
tamate (12) (Fig.  2).  To test the role of the pyroglutamate 
in determining function, nine MCP-1 analogues varying in 
the NH2-terminal residue were synthesized according to the 
sequences shown in Fig. 2. To prevent pyroglutamate forma- 
tion, we acetylated the NH2-terminus to form the MCPol 
(Ac) analogue, and found that the chemotactic potency was 
300-fold reduced compared to the pyroglutamate form (Fig. 
3 A). Addition of alanine, which corresponds to the last res- 
idue of the signal peptide (MCP, Ala -1, Fig. 2), or deletion 
of the NH2-terminal pyroglutamate (2-76 analogue) resulted 
a similar loss  of activity. 
Despite these results,  replacement of the NH2-terminal 
MCP-I 
MCP-1  (Ac) 
MCP-I  (Ala  -I) 
MCP-I  (Asn  I  ) 
MCP-I  (AcAsn  I  ) 
MCP-I  (Asp  I) 
MCP-1  (Ala  I) 
MCP-I  (Aba  I) 
MCP-I  (nVal  I  ) 
2-76  analog 
3-76 analog 
4-76 analog 
5-76 analog 
6-76 analog 
7-76 analog 
8-76 analog 
9-76 analog 
10-76 analog 
11-76  analog 
1  2  3  4 
<Glu  Pro  Asp  Ala 
AcGIn  Pro  Asp  Ala 
Ala  Gln  Pro  Asp  Ala 
Asn  Pro  Asp  Ala 
AcAsn  Pro  Asp  Ala 
Asp  Pro  Asp  Ala 
Ala  Pro  Asp  Ala 
Aba  Pro  Asp  Ala 
nVal  Pro  Asp  Ala 
Pro  Asp  Ala 
ASp  Ala 
Ala 
5  6  7  8  9  10  ii  12 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Ash  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ile  Ash  Ala  Pro  Val  Thr  Cys  Cys 
Ile  ASh  Ala  Pro  Val  Thr  Cys  Cys 
Asn  Ala  Pro  Val  Thr  Cys  Cys 
Ala  Pro  Val  Thr  Cys  Cys 
Pro  Val  Thr  Cys  Cys 
Val  Thr  Cys  Cys 
Thr  Cys  Cys 
Cys  Cys 
Figure  2.  NHz-terminal se- 
quences of MCP-1 analogues with 
modifications  to  the  NH2-ter- 
minal ten residues. The wild-type 
MCP-1 sequence is listed on top. 
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Figure 3.  Chemotactic  activity of MCP-1 analogues that are modified 
at the NH2-terminal residue. The analogues (Fig. 2) were titrated in assays 
for THP-1  chemotaxis as described for Fig.  1.  MCP-1, MCP-1 (Ash I ), 
MCP-1 (Ala~),  and MCP-1 (riVal I ) were not significantly different; how- 
ever the remaining analogues were significantly different from  MCP-1 
(p <0.05).  Results  shown are representative of two experiments. 
pyroglutamate with asparagine (MCP-1, Ash  1) resulted in an 
analogue with full activity (Fig. 3 A). As with the wild type, 
acetylation of the NH2 terminus of MCP-1, Asn  t consider- 
ably reduced activity, suggesting that the acetylation alone, 
rather  than  prevention  of pyroglutamate formation,  was 
responsible for the loss of  potency. Asparagine and pyrogluta- 
mate are smaller than glutamine, so to test the effects of side 
chain size on function, the nonpolar residues Ala (-CH3), 
Aba (-CH2CH3), and nVal (-CH2CH2CH3) were substituted. 
All three were highly active and similar in potency to MCP-1 
(Fig. 3 B).  Interestingly,  the MCpol (Aba 1) was threefold 
more active than MCP-1. In contrast, aspartic acid was not 
tolerated  at  the NH2-terminal  position (Fig. 3 B).  Induc- 
tion of cytoplasmic free Ca  2+ generally correlated with the 
chemotaxis results (not shown). The 2-76 analogue and MCP-1 
(Ac) were assayed for binding to the MCP-1 receptor(s) by 
competition with labeled MCP-1. From the binding curves 
shown in Fig. 4 A, MCP-1, the 2-76 and MCP-1 (Ac) aria- 
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Figure 4.  Receptor binding of MCP-1 analogues. The indicated con- 
centrations  of MCP-1 analogues (Fig. 2) were added to THP-1 cells in 
the presence of 4 nM 12SI-MCP-1. Nonspecific binding was subtracted 
from  total binding, and the results expressed as  %  maximum specific 
binding. Results are representative of two experiments. 
logues had Kas of 2.8, 385, and 333 nM, respectively. For 
these two analogues, this corresponds to greater than 100- 
fold loss in binding a~nity, which correlates with the de- 
crease in functional activity relative to MCP-1. These results 
indicate that the integrity of a residue at the NH2 terminus 
of MCP-1 is critical for binding and function, but that the 
wild-type pyroglutamate is not essential. 
Activity of NH2-terminally Truncated  Analogues.  To further 
examine the role of the NH2-terminal region in determining 
function, we designed a series of analogues that were short- 
ened at the NH2 terminus (Fig. 2). When they were exam- 
ined for THP-1 chemotaxis, the natural 1-76 form (MCP-1) 
had the highest activity, the 2-76 analogue was 300-fold lower 
whereas the 3-76 and 4-76 analogues had only marginal ac- 
tivity (Fig. 5 A). Surprisingly, the 5-76 analogue had readily 
detectable activity  (2/3 the level of migration of MCP-1), 
and was only fourfold less potent than MCP-1 (Fig. 5 B). 
The 6-76 analogue had lower, but significant chemotactic 
activity. The remaining shortened analogues, 7-76, 8-76, 9-76, 
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Figure 5.  Chemotactic  activity of NH2-terminal truncated analogues. 
The indicated analogues  (Fig. 2) were  titrated in the THP-1 cell  chemotaxis 
assay as described  for Fig. 1. MCP-1 and 5-76 were significantly different 
from each other and from the remaining analogues (p <0.05). Except for 
the  1-10 peptide, MCP-1, 2-76, 3-76, 4-76, 5-76, and 6-76 were all 
significantly different than the negative  control (p <0.05). Results shown 
are representative of three experiments. 
10-76, and 11-76, lacked detectable chemotactic activity (Fig. 
5 B). A peptide corresponding to residues 1-10 (Fig.  2) also 
lacked detectable activity (Fig. 5 A). Similar results were ob- 
tained with monocytes as the target cells (data not shown). 
Ca 2+ Mobilization  and Desensitization  by  Truncation Ana- 
logues.  Transient  intracellular  Ca  2+  mobilization  was  as- 
sayed as a second measure of function.  The native MCP-1 
was the most efficient in inducing cytosolic Ca 2+ mobiliza- 
tion of the analogues tested (Figs. 6 and 7 A). However, con- 
sistent with its chemotactic activity, the 5-76 analogue also 
induced  a Ca  2+ rise in  THP-1 cells  (Figs.  6 and  7 A).  As 
summarized in Fig. 7 A, the 2-76, 4-76, and 6-76 analogues 
induced a lower response. The 3-76, 7-76, 8-76, 9-76, 10-76, 
and 11-76 analogues (Figs.  6 and 7 A) or the 1-10 peptide 
(not  shown)  did  not  induce  significant  cytosolic Ca  2+  at 
levels up to  1,000 nM. 
After treatment with an MCP-1 receptor ligand,  the cal- 
cium response is temporally desensitized to treatment with 
a second MCP-1 receptor ligand. When the analogues were 
examined for their ability to desensitize the subsequent Ca  2+ 
response to MCP-1, there was little correspondence with the 
Ca  z+ induction results (Figs.  6 and 7 B). All truncated ana- 
logues desensitized THP-1 cells to a subsequent MCP-1 chal- 
lenge,  although  the 11-76 analogue required a higher con- 
centration 1,000 nM for a detectable response. The MCP-1, 
1-10  peptide  did  not  attenuate  the  Ca  2+  response  (not 
shown). Most significantly, the 3-76,  7-76, 8-76, 9-76, and 
10-76 analogues desensitized but did not induce Ca  2+ (com- 
pare Fig. 7, A  and/3).  Of the noninducing analogues, 9-76 
was consistently the most effective at desensitization.  The 
results indicate that  several truncated analogues desensitize 
MCP-1 receptors, but do not activate Ca2+-dependent  sig- 
naling. 
Receptor  Binding of Truncated  Analogues.  Several  of the short- 
ened analogues were tested for MCP-1 receptor binding by 
competition for t25I-MCP-1  (Fig.  4). The 2-76 and 3-76 an- 
alogues had Kds (385 and 487 nM, respectively) ~150-fold 
higher than MCP-1 (Ka 2.8 riM) when analyzed for binding 
on THP-1  cells (Fig.  4 A).  In keeping with  its functional 
activity, the 5-76 analogue had only an eightfold higher Kd 
(23 nM) than MCP-1. The inactive 9-76 analogue had three- 
fold higher Kd than MCP-1, whereas the Kds of 10-76  and 
11-76 analogues were 13-  and 48-fold higher,  respectively. 
The MCP-1 (1-10) peptide did not bind (Fig. 4 B ). The 9-76 
and 11-76 analogues were labeled, and direct binding assays 
were performed (not shown). The binding results correlated 
well with  the Ca  2+ desensitization  results. 
Inhibition of MCP-1 Chemotaxis Activity.  The ability of the 
non-chemotactic analogues to desensitize calcium mobiliza- 
tion of MCP-1 suggested that they were binding to MCP-1 
receptors but not activating  the signaling  pathways of the 
receptor(s).  If this hypothesis is correct,  then it would be 
expected that  they would block the biological response in- 
duced by MCP-1 through a competitive binding mechanism. 
To test this, the 8-76, 9-76, 10-76, and 11-76 analogues were 
titrated in the presence of 5 nM MCP-1 (Fig.  8).  The four 
analogues inhibited MCP-l-stimulated chemotaxis in a dose- 
dependent manner.  The 9-76 analogue was the most potent 
(IC50  =  20 nM),  the 8-76 analogue was threefold less po- 
tent  (ICs0  =  60 riM),  and the 10-76  and  11-76  analogues 
were much less potent (IC50 -- 0.6 and 1/zM, respectively). 
The 1-10 peptide did not significantly inhibit chemotaxis (not 
shown). 
Specificity of 9-76 Antagonists.  The ligand-receptor  spe- 
cificity of the 9-76 analogue was tested by desensitization of 
Ca  2+ induction.  Chemokine ligands  transiently desensitize 
their own receptor but not other receptors (15).  As shown 
in Fig.  9,  the 9-76 analogue desensitized the Ca  2+ mobili- 
zation  in  response  to  MCP-1  and  MCP-3,  but  did  not 
significantly decrease the response to RANTES, MIP-lcr, or 
MIP-I~/.  In addition, the 9-76 analogue was able to specifically 
block MCP-I-,  MCP-2-,  and MCP-3-induced cell migra- 
tion,  but not  that  induced by MIP-loe and RANTES,  up 
to  1,000-fold molar  excess  (data not  shown).  Overall,  the 
results suggest that the inhibition of MCP-1 and MCP-3 in- 
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Figure  6.  CF § mobilization and 
desensitization  of  the  indicated 
NH2-terminal truncation analogues. 
The  transient  rise in fluorescence 
intensity was measured after initial 
treatment  of  Fluo-3AM  loaded 
THP-1  cells  with  the  indicated 
MCP-1  analogues  and  again  on 
challenge with MCP-1 as indicated. 
Results are representative of at least 
two  experiments.  Over  many ex- 
periments,  the  calcium  response 
was found not to be significant at 
values under 5% fluorescence satu- 
ration.  Therefore,  the  induction 
with  the  3-76,  8-76,  9-76,  and 
11-76 analogues is not significant. 
The MCP-1 response after the 9-76 
analogue  treatment  is  also  not 
significant. 
duced chemotaxis is correlated with ability to desensitize the 
MCP-1 receptor without concomitant activation. 
Discussion 
Analogues  of MCP-1  were  analyzed  for  function and 
receptor interactions using monocytes and THpol, a mono- 
cyte cell line. Our results indicate that the NH2-terminal re- 
gion is critical for receptor binding and function, and that 
some analogues, e.g., the 9-76 analogue, have receptor an- 
tagonist properties, suggesting that receptor binding can be 
dissociated from functional receptor activation. 
Comparison of CC chemokines indicated that MCpol and 
MCPo3 stimulated chemotaxis via common receptors. MCP-2 
also stimulated chemotaxis, but was the least potent of the 
three (data not shown). RANTES, MIP-lol,  and MIP-1B 
stimulated  a transient  increase in cytosolic Ca  2+ levels, but 
had only weak chemotaxis activity. The actions of these CC 
chemokines  appeared to be mediated by distinct  receptors 
(15, 19-23). We observed some desensitization of MIP-loJ 
RANTES receptors with high concentrations of MCP-1, but 
whether this cross-reaction has apparent  physiological sig- 
nificance  is uncertain. Overall, the results indicate that amongst 
the CC chemokines,  MCP-1 is the most potent monocyte 
chemoattractant and is the ligand  of choice for structure- 
activity relationships involving the MCP-1 receptor. 
Residues within the NH2-terminal region 1-10 of MCP-1 
are essential for chemotaxis and receptor signaling, as demon- 
strated by the lack of chemotactic activity of the 11-76 ana- 
logue. The nature of the NH2-terminal residue is critical as 
deletion  or modification  of the N ~ group by acetylation 
resulted in substantial loss of activity. Nevertheless, asparagine 
or nonpolar  residues of various sizes could fully substitute 
for pyroglutamate.  Thus the integrity of the NH2-terminal 
residue  is essential  for function but the side chain can be varied. 
This suggests that either it may form important secondary 
structure elements  within MCP-1 rather than interacting 
directly with the receptor, or that the backbone component 
of the residue fits tightly into the binding pocket, such that 
an N-acetyl group cannot be accommodated, but its side chain 
can be varied. 
Deletion of the first two amino acids resulted in almost 
total loss of activity, but surprisingly, activity was regained 
on deletion of further amino acids. The 5-76 analogue had 
only fourfold lower potency than full-length MCP-1. Receptor 
binding a~nities correlated with the functional activities. This 
suggests that the NH2-terminal  residue is not essential for 
signaling, but  may be required  for maximal  binding (see 
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Figure  7.  Summary of stimulation  and desensitization of Ca  2+ induc- 
tion by truncated  MCP-I analogues. A  shows the percent  of Fluo-3 AM 
saturation  (Materials and  Methods)  at  10 nM,  100 nM,  and  1,000 nM 
analogue  concentration.  By the criteria outlined in Fig. 6, the response 
of the 3,76, 7-76, 8-76, 9-76, 10-76, and 11-76 analogues were not significant 
at any dose tested. B shows the percentage desensitization  induced by the 
truncated  analogues  at 10 nM,  100 nM, or 1,000 nM, to a subsequent 
treatment by 10 nM MCP-1. Maximal desensitization  of fluorescence ob- 
tained with MCP-1 was designated as 100% desensitization  and the max- 
imal fluorescence induced by 10 nM MCP-1 was designated as 0% desen- 
sitization.  All the analogues gave significant  desensitization  for at least 
one of the doses tested. 
above). With further deletions from the 5-76 analogue, bio- 
logical activity was lost but receptor binding and desensiti- 
zation was retained with the 8-76,  9-76,  10-76,  and  11-76 
analogues.  Thus,  receptor binding,  within  residues 7-10 is 
dissociated from receptor activation that requires residues 1-6. 
The loss regaining and subsequent loss of activity upon se- 
quential truncation suggests that multiple NH2-terminal re- 
gion are required for full activity, and partial deletions can 
have a negative effect on receptor interactions.  Consistent with 
these findings, residues 1, 2, 6, 9, and 10 are either identical 
or conservatively substituted when the sequences of MCP-1, 
MCP-2, and MCP-3 are compared.  The fact that the NH2- 
terminal peptide 1-10 did not bind or display agonist or an- 
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Figure  8.  MCP-1  antagonist  activity of truncated  MCP-1 analogues. 
Constant  MCP-1 (5  x  10 -9 M) was added to each well and the indicated 
analogues were titrated  in the THP-1  chemotaxis  assay as described for 
Fig.  1.  The 10-76  and  11-76 were not significantly  different  from each 
other. However, either 10-76 or 11-76, and all the other remaining  ana- 
logues were significantly  different  from the MCP-1  control (p <0.05). 
Results  are representative  of three  experiments. 
tagonist activity suggests that additional residues or regions 
within the 11-76 analogue are also required for function. Re- 
sidual receptor binding was detected with the 11-76 analogue, 
indicating that receptor binding motifs are also contained in 
residues  11-76. 
The observations with MCP-1 have parallels  with IL-8, a 
member of the structurally related CXC chemokine family. 
In the case of IL8,  the NH2-terminal  residues 4,  5,  and 6 
are  essential  for receptor binding  and  triggering  function 
(30-32). Interestingly, the three residues which in the aligned 
sequences correspond to IL-8, 4-6 are MCP-1, 8-10.  These 
three residues are part  of an MCP-1 receptor-binding  site. 
In addition, the MCP-1 situation is more complex than that 
of Ib8, in that the functionally critical  NH2-terminal region 
extends over 10 residues and in addition to 8, 9, and 10, residues 
1-7 are also required for activity.  The three-dimensional struc- 
ture of MCP-1 may assist in determining the roles of residues 
1-10 but the NHz-terminal regions of chemokines are often 
partially disordered (37, 38), making it difficult to suggest 
functional  roles.  As proposed here  for MCP-1,  additional 
downstream residues are also required for IL-8 structure-func- 
tion  (39). 
Two truncated analogues, MCP-1, 8-76 and 9-76 were po- 
tent inhibitors of MCP-1 function. The 3-76, 7-76 (data not 
shown),  10-76,  and 11-76 analogues were less potent.  The 
inhibition potency correlated with their receptor affinity. The 
ability of these analogues to desensitize the calcium response 
induced by MCP-1 and MCP-3, coupled with their inability 
to induce Ca  2+ mobilization, suggests that they bind to, but 
cannot activate MCP-receptors. The mechanism of transient 
cbemotactic receptor desensitization is not known, but our 
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Figure  9.  Specificity of the 9-76 antagonist. The ability of the 9-76 
analogue to desensitize the subsequent Ca  2§ response by the indicated CC 
chemokines was measured.  By the criteria described for Fig. 6,  the re- 
sponse of 9-76 was not significant, nor was the MCP-1 or MCP-3 response 
after 9-76  treatment. Results are representative  of three experiments. 
results  suggest  that  receptor activation  is  not  necessary. 
Receptor binding is likely to be a requirement for desensiti- 
zation,  as demonstrated by mechanistic  studies suggesting 
receptor occupancy (40) and internalization  (41) are involved 
for the related FMLP receptor. Thus, our desensitization  results 
reflect receptor occupancy. 
The 9-76 analogue inhibited THPol cell migration induced 
by MCP-1 (Fig. 8), and MCP-3, but not by RANTES, MIP- 
lc~, or MIP-I~ (data not shown), further supporting the desen- 
sitization data indicating that the 9-76 analogue is specific 
for the MCP receptors  and not RANTES or MIP-lo~  receptors. 
The  9-76 analogue  was  the  most  potent  antagonist  of 
chemotaxis tested: 20 nM inhibited 5 nM of MCP-1 by 50% 
(ICs0  =  20 nM). This correlated with the receptor binding 
studies showing that 17 nM 9-76 analogue displaced 4 nM 
of MCpol by 50%. The binding affinity calculated for 9-76 
was threefold lower than MCP-1 (Kd 8.3 nM and 2.8 nM, 
respectively). By comparison, the 50% of maximal effective 
dose (EDs0) for MCP-1 chemotaxis activity was around 10 -9 
nM. The potency of the MCP-1 antagonist was 15-fold  higher 
than that of the truncated I1.,8 antagonists previously  described 
(32). NH2-terminal deletion of chemokines may be a general 
method of dissociation of receptor binding from function, 
thus generating antagonists. 
We predict that the 9-76 antagonist  will be in the ther- 
apeutic range of effectiveness and will be useful for evalu- 
ating MCP-1 antagonists in animal models, such as the rat 
alveolitis system where anti-MCP-1 antibodies  have been 
reported to inhibit in vivo function (29). As excess  antagonist 
is always required to completely block a response by a com- 
petitive mechanism, higher affinity antagonists will be even 
more effective.  Furthermore, the 9-76 analogue is not expected 
to be orally active, and although pharmakokinetic studies have 
not yet been done, it may be readily adsorbed, excreted and 
degraded. 
The discovery of the 9-76 antagonist  provides a lead for 
development of further MCP-receptor antagonists with high 
potency. Future studies that include more detailed analysis 
of the NH2-terminal region and determination of the roles 
of other regions of MCP-1 in structure-function could help 
provide improved antagonists.  The combination of in vivo 
studies with further structure-function analysis should pro- 
vide second generation antagonists that may have therapeutic 
value. 
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Note added in proof." After submission of this manuscript,  a report appeared describing partial inhibition 
of MCP-1 activity on human peripheral-blood monocytes by MCP-1 deletion mutants (Zhang, Y. J., B. T. 
Rutledge,  and B. J.  Rollins.  Structure/activity analysis of human  monocyte chemoattractant  protein-1 
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